Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674521 | PMC |
| http://dx.doi.org/10.1186/s13054-021-03859-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
J Hepatol
July 2023
Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India; Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. Electronic address:
Background & Aims: Hepatopulmonary syndrome (HPS) is characterised by a defect in arterial oxygenation induced by pulmonary vascular dilatation in patients with liver disease. Fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, suppresses vasodilation by reducing nitric oxide (NO) production. We investigated the role of S1P in patients with HPS and the role of fingolimod as a therapeutic option in an experimental model of HPS.
View Article and Find Full Text PDFOrthodeoxia and its implications on awake-proning in COVID-19 pneumonia.
Crit Care
December 2021
Department of Anesthesia and Critical Care, AOU S. Luigi Gonzaga, Turin, Italy.
Clinical and echocardiographic outcomes after percutaneous closure of patent foramen ovale: a single center experience.
Minerva Cardiol Angiol
April 2023
Division of Thoracic and Cardiovascular Surgery, Pontchaillou University Hospital, Rennes, France -
Background: Patent foramen ovale (PFO) has a high estimated prevalence (25% of the general population) and has been implicated in the pathogenesis of cryptogenic stroke and transient ischemic attack (TIA), as well as in the pathogenesis of migraine headache. This study evaluated the effectiveness of percutaneous transcatheter PFO closure with Amplatzer (Abbott Laboratories, Abbott Park, IL, USA) devices, from a large single-center experience.
Methods: From January 1998 to December 2014, 577 patients (243 males and 334 females, mean age 50 years, range 11-82 years) with documented PFO and history of at least one episode of cryptogenic stroke/TIA (N.
Treatment of Platypnea-Orthodeoxia Syndrome in a Patient with Normal Cardiac Hemodynamics: A Review of Mechanisms with Implications for Management.
Methodist Debakey Cardiovasc J
October 2018
CORE PHYSICIANS, EXETER, NEW HAMPSHIRE.
Platypnea-orthodeoxia syndrome is a rare entity characterized by dyspnea and hypoxemia in the sitting position and usually resolved by lying down. Although it is not well understood, it is thought to be associated with either intracardiac or extracardiac factors. Within the group of intracardiac etiologies, it typically occurs in the presence of right heart failure or elevated right-sided filling pressures.
View Article and Find Full Text PDFTo close or not to close: contemporary indications for patent foramen ovale closure.
Expert Rev Cardiovasc Ther
November 2016
a Department of Medicine, Division of Cardiology , University of California, San Francisco , San Francisco , CA , USA.
Patent foramen ovale (PFO) is a common congenital cardiac abnormality and that has been associated with several disease processes including transient ischemic attacks (TIA), stroke, migraine headaches with aura, decompression sickness, platypnea-orthodeoxia syndrome, and shunt induced cyanosis. Controversy exists regarding closure of PFO as a therapeutic treatment modality for these disease processes. This review addresses the contemporary clinical indications for PFO closure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!